Suven Life Sciences (Suven) shares gained on Thursday after grant of one product patent from Hong Kong and one product patent from Canada corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2023 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

Shares of the company are trading at Rs 77.70, up Rs 2.35, or 3.12% at the Bombay Stock Exchange (BSE) on Thursday at 10:34 a.m.

The scrip has touched an intra-day high of Rs 78.95 and low of Rs 75.00. The total volume of shares traded at the BSE is 299,071.
In the earlier session, the shares rose 1.41%, or Rs 1.05, at Rs 75.35.

Currently, the stock is trading down 6.83% from its 52-week high of Rs 83.40 and above 253.18% over the 52-week low of Rs 22.